Searched for: in-biosketch:true
person:underj01
Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: Proceedings from a workshop
Cohen, Jerome D; Aspry, Karen E; Brown, Alan S; Foody, Joanne M; Furman, Roy; Jacobson, Terry A; Karalis, Dean G; Kris-Etherton, Penny M; Laforge, Ralph; O'Toole, Michael F; Scott, Ronald D; Underberg, James A; Valuck, Thomas B; Willard, Kaye-Eileen; Ziajka, Paul E; Ito, Matthew K
The workshop discussions focused on how low-density lipoprotein cholesterol (LDL-C) goal attainment can be enhanced with the use of health information technology (HIT) in different clinical settings. A gap is acknowledged in LDL-C goal attainment, but because of the passage of the American Recovery & Reinvestment Act and the Health Information Technology for Economic and Clinical Health Acts there is now reason for optimism that this gap can be narrowed. For HIT to be effectively used to achieve treatment goals, it must be implemented in a setting in which the health care team is fully committed to achieving these goals. Implementation of HIT alone has not resulted in reducing the gap. It is critical to build an effective management strategy into the HIT platform without increasing the overall work/time burden on staff. By enhancing communication between the health care team and the patient, more timely adjustments to treatment plans can be made with greater opportunity for LDL-C goal attainment and improved efficiency in the long run. Patients would be encouraged to take a more active role. Support tools are available. The National Lipid Association has developed a toolkit designed to improve patient compliance and could be modified for use in an HIT system. The importance of a collaborative approach between nongovernmental organizations such as the National Lipid Association, National Quality Forum, HIT partners, and other members of the health care industry offers the best opportunity for long-term success and the real possibility that such efforts could be applied to other chronic conditions, for example, diabetes and hypertension.
PMID: 24314357
ISSN: 1876-4789
CID: 712122
Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values
Rosenson, Robert S; Underberg, James A
PURPOSE: This systematic review was performed to summarize published experience using low density lipoprotein particle number (LDL-P) to monitor the efficacy of lipid-lowering pharmacotherapies. METHODS: Studies were identified from a literature search of MEDLINE (January 1, 2000 - June 30, 2012); and abstract searches of select conferences. All accepted studies reported mean (or median) nuclear magnetic resonance (NMR)-based LDL-P values for at least 10 subjects receiving lipid lowering pharmacotherapy. RESULTS: Searches revealed 36 studies (with 61 treatment arms) in which LDL-P measurements were reported pre- and post-treatment. Most studies also reported changes in low-density lipoprotein cholesterol (LDL-C), but fewer studies reported changes in apolipoprotein B (apoB)(n = 20) and non-HDL-C (n = 28). Treatments included statins (22 arms/15 studies), fibrates (7 arms/7studies), niacin (7 arms/6 studies), bile acid sequestrants (5 arms/2 studies), an anti-apoB oligonucleotide (2 arms/2 studies), combination therapies (8 arms/6 studies), anti-diabetics (5 arms/4 studies), and, other treatments (5 arms/2 studies). Lipid-lowering pharmacotherapy resulted in reductions in mean LDL-P in all but two studies. In several statin studies, the percent reductions in LDL-P were smaller than reductions in LDL-C, comparable changes were reported when LDL-P and apoB, were reported. CONCLUSIONS: Study-level data from this systemic review establish that different lipid lowering agents can lead to discordance between LDL-P and LDL-C, therefore, basing LDL-lowering therapy only on the achievement of cholesterol goals may result in a treatment gap. Therefore, the use of LDL-P for monitoring lipid-lowering therapy, particularly for statins, can provide a more accurate assessment of residual cardiovascular risk.
PMCID:3777154
PMID: 23893306
ISSN: 0920-3206
CID: 576002
New Treatment Approaches for Dyslipidemia and its Management
Vorsanger, M; Underberg, J A
The field of lipidology is evolving rapidly. Two novel medications have recently been approved for use in homozygous familial hypercholesterolemia (HoFH); the Apolipoprotein B (Apo B) mRNA antisense oligonucleotide (ASO), mipomersen (Kynamro) and the microsomal triglyceride transfer protein (MTP) inhibitor, lomitapide (Juxtapid). Equally important have been the disappointments in cholesterol research; the halting of further investigation into the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib, yet two others remain in development. The failure of the combination of extended release niacin and laropiprant to show benefit when combined with statin therapy has lead to the discontinuation of this product in Europe. Perhaps one of the most exciting avenues of future research is into the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). 2013 Springer Science+Business Media New York
EMBASE:2013581253
ISSN: 1932-9520
CID: 549762
Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients
Chapter by: Tran, Henry A; Schwartzbard, Arthur Z; Underberg, James A
in: Lipoproteins in Diabetes Mellitus by Jenkins, Alicia J; Toth, Peter P; Lyons, Timothy J [Eds]
[S.l.] : Humana Press, 2013
pp. 399-413
ISBN:
CID: 1795342
2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards)
Cannon, Christopher P; Brindis, Ralph G; Chaitman, Bernard R; Cohen, David J; Cross, J Thomas Jr; Drozda, Joseph P Jr; Fesmire, Francis M; Fintel, Dan J; Fonarow, Gregg C; Fox, Keith A; Gray, Darryl T; Harrington, Robert A; Hicks, Karen A; Hollander, Judd E; Krumholz, Harlan; Labarthe, Darwin R; Long, Janet B; Mascette, Alice M; Meyer, Connie; Peterson, Eric D; Radford, Martha J; Roe, Matthew T; Richmann, James B; Selker, Harry P; Shahian, David M; Shaw, Richard E; Sprenger, Sharon; Swor, Robert; Underberg, James A; Van de Werf, Frans; Weiner, Bonnie H; Weintraub, William S
PMID: 23680811
ISSN: 1535-2811
CID: 779952
2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards)
Cannon, Christopher P; Brindis, Ralph G; Chaitman, Bernard R; Cohen, David J; Cross, J Thomas Jr; Drozda, Joseph P Jr; Fesmire, Francis M; Fintel, Dan J; Fonarow, Gregg C; Fox, Keith A; Gray, Darryl T; Harrington, Robert A; Hicks, Karen A; Hollander, Judd E; Krumholz, Harlan; Labarthe, Darwin R; Long, Janet B; Mascette, Alice M; Meyer, Connie; Peterson, Eric D; Radford, Martha J; Roe, Matthew T; Richmann, James B; Selker, Harry P; Shahian, David M; Shaw, Richard E; Sprenger, Sharon; Swor, Robert; Underberg, James A; Van de Werf, Frans; Weiner, Bonnie H; Weintraub, William S
PMCID:5681220
PMID: 23369353
ISSN: 0735-1097
CID: 779972
2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards)
Cannon, Christopher P; Brindis, Ralph G; Chaitman, Bernard R; Cohen, David J; Cross, J Thomas Jr; Drozda, Joseph P Jr; Fesmire, Francis M; Fintel, Dan J; Fonarow, Gregg C; Fox, Keith A; Gray, Darryl T; Harrington, Robert A; Hicks, Karen A; Hollander, Judd E; Krumholz, Harlan; Labarthe, Darwin R; Long, Janet B; Mascette, Alice M; Meyer, Connie; Peterson, Eric D; Radford, Martha J; Roe, Matthew T; Richmann, James B; Selker, Harry P; Shahian, David M; Shaw, Richard E; Sprenger, Sharon; Swor, Robert; Underberg, James A; Van de Werf, Frans; Weiner, Bonnie H; Weintraub, William S
PMID: 23357718
ISSN: 0009-7322
CID: 779962
Improving Outcomes in Patients with Severe Familial Hypercholesterolemia
McGowan, M P; Underberg, J A; Rader, D J
EMBASE:2013987949
ISSN: 1876-4789
CID: 5158392
Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management
Williams, Stephen K; Ravenell, Joseph; Jean-Louis, Girardin; Zizi, Ferdinand; Underberg, James A; McFarlane, Samy I; Ogedegbe, Gbenga
Resistant hypertension is common among adults with hypertension affecting up to 30% of patients. The treatment of resistant hypertension is important because suboptimal blood pressure control is the leading preventable cause of death worldwide. A frequent comorbid condition in patients with resistant hypertension is obstructive sleep apnea. The pathophysiology of sleep apnea-associated hypertension is characterized by sustained adrenergic activation and volume retention often posing treatment challenges in patients with resistant hypertension. This review will address some of the epidemiologic data associating apnea with the pathogenesis of resistant hypertension. Diagnosis and management of apnea and its associated hypertension will also be considered
PMID: 21104207
ISSN: 1539-0829
CID: 138271
ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association [Guideline]
Bairey Merz, C Noel; Alberts, Mark J; Balady, Gary J; Ballantyne, Christie M; Berra, Kathy; Black, Henry R; Blumenthal, Roger S; Davidson, Michael H; Fazio, Sara B; Ferdinand, Keith C; Fine, Lawrence J; Fonseca, Vivian; Franklin, Barry A; McBride, Patrick E; Mensah, George A; Merli, Geno J; O'Gara, Patrick T; Thompson, Paul D; Underberg, James A
PMCID:2782747
PMID: 19778678
ISSN: 1558-3597
CID: 109385